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Number of left ventricular assist device (LVAD) implanta-
tions increases every year, particularly LVADs for destination 
therapy (DT). Right ventricular failure (RVF) has been recog-
nized as a serious complication of LVAD implantation. Re-
ported incidence of RVF after LVAD ranges from 6% to 44%, 
varying mostly due to differences in RVF definition, differ-
ent types of LVADs, and differences in patient populations 
included in studies. RVF complicating LVAD implantation 
is associated with worse postoperative mortality and mor-
bidity including worse end-organ function, longer hospital 
length of stay, and lower success of bridge to transplant 
(BTT) therapy. Importance of RVF and its predictors in a 
setting of LVAD implantation has been recognized early, as 
evidenced by abundant number of attempts to identify in-
dependent risk factors and develop RVF predictor scores 
with a common purpose to improve patient selection and 
outcomes by recognizing potential need for biventricular 
assist device (BiVAD) at the time of LVAD implantation. The 
aim of this article is to review and summarize current body 
of knowledge on risk factors and prediction scores of RVF 
after LVAD implantation. Despite abundance of studies and 
proposed risk scores for RVF following LVAD, certain com-
mon limitations make their implementation and clinical 
usefulness questionable. Regardless, value of these stud-
ies lies in providing information on potential key predictors 
for RVF that can be taken into account in clinical decision 
making. Further investigation of current predictors and ex-
isting scores as well as new studies involving larger patient 
populations and more sophisticated statistical prediction 
models are necessary. Additionally, a short description of 
our empirical institutional approach to management of 
RVF following LVAD implantation is provided.
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Heart failure is one of the most common causes of death in 
western world. Number of patients diagnosed with heart 
failure is growing and it remains a target for many pre-
ventive and treatment efforts (1,2). Mechanical circulatory 
support (MCS) devices, including ventricular assist devices 
(VADs) represent an important treatment modality. Given 
common etiology of end stage heart failure, left ventricu-
lar assist devices (LVADs) are of greater interest. Right ven-
tricular assist devices (RVADs) are reserved for situations in 
which right ventricular failure (RVF) develops, usually as 
pathophysiological sequels of left ventricular failure (LVF) 
or LVAD implantation (Figure 1 and 2).
Indications for LVAD implantation include: 1. bridge to 
transplantation (BTT); 2. bridge to candidacy for transplan-
tation; 3. destination therapy (DT), ie, patients who are not 
suitable for transplantation; and 4. temporary support for 
patients whose cardiac function is expected to recover.
Scientific and technological improvements of LVAD im-
plantation, as well as perioperative medical management 
have led to significant reduction in complication rates, and 
improved survival and quality of life, all leading to out-
comes approaching those achieved with heart transplant 
(3-8). Therefore, it is not surprising that overall rate of LVAD 
implantation increases every year, especially the number 
of LVADs for destination therapy (9) (Figure 3).
RVF has been recognized as a serious complication of 
LVAD implantation, and as such has been a subject of con-
siderable research. The purpose of this article is to review 
existing literature on predictors and risk scores for RVF fol-
lowing LVAD implantation. To identify studies of interest 
we used MEDLINE search with Boolean term “AND,” limited 
Figure 1. illustration of Heart Mate ii (Thoratec, Pleasanton, 
CA, uSA) implantation. reprinted with permission, Cleveland 
Clinic Center for Medical Art & Photography ©2002. All rights 
reserved.
Figure 2. illustration of Thoratec PVAD (Thoratec, Pleasanton, 
CA, uSA) (left ventricular assist device [LVAD], right ventricular 
assist device [rVAD], and biventricular assist device [BiVAD]). 
reprinted with permission, Cleveland Clinic Center for Medical 
Art & Photography ©2002. All rights reserved.
Figure 3. Trend of left ventricular assist device (LVAD) implan-
tations in last seven years, per iNTerMACS Quarterly Statistical 
report, 1st Quarter, 2014 (https://www.uab.edu/medicine/
intermacs/images/CMS/CMS_report_2012_Q4.pdf)
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to Title/Abstract and English language using terms “RV fail-
ure,” “LVAD,” and “predictors,” which yielded 15 articles. Cita-
tion indexing on the included studies was done to screen 
for other relevant publications not identified by our search 
strategy, which yielded additional 40 articles that were re-
viewed in detail. After careful review of these 55 articles, 
we have identified a total of 11 studies that developed 
original prediction models for right ventricular failure af-
ter LVAD. Of these 11 studies, 7 used available preoperative 
and intraoperative demographic, laboratory and comor-
bidity variables in their models (Supplementary table 1). 
The remaining 4 studies used echocardiographic variables 
(Supplementary table 2).
iMPOrTANCe OF rigHT VeNTriCuLAr FAiLure AFTer 
LeFT VeNTriCuLAr DeViCe iMPLANTATiON
Many definitions of RVF after LVAD have been used. Most 
common definition describes RVF after LVAD as need for 
intravenous inotrope or pulmonary vasodilator therapy for 
14 days postoperatively and/or need for RVAD implanta-
tion (10-14). A few studies defined RVF as requirement for 
RVAD only (15,16), whereas others used two or more of the 
following hemodynamic parameters to define RVF; cen-
tral venous pressure greater than 16 mm Hg, mean arterial 
pressure lower than 55 mm Hg, cardiac index lesser than 2 
L/min/m2, inotropic support more than 20 units, mixed ve-
nous saturation lower than 55%, all in the absence of car-
diac tamponade (17).
Reported incidence of RVF after LVAD varies from 6% to 
44% (10-12,14,16,18-33). This is mostly due to differences in 
definitions of RVF, different types of LVADs (continuous vs 
pulsatile), and differences in patient populations.
Patients who develop RVF have higher incidence of end 
organ dysfunction, and overall worse morbidity and mor-
tality. In addition, RVAD implantation as a treatment op-
tion for RVF leads to increased morbidity secondary to 
increased infection risk, need for transfusion, and risk of 
device failure. Therefore, one of the most important issues 
since introduction of LVAD as treatment for heart failure 
has been to determine the need and optimal timing of 
RVAD support.
There have been many studies that developed prediction 
models and scores for RVF risk after LVAD, with common 
purpose to improve patient selection, and successfully 
predict the need for BiVAD at initial surgery, possibly lead-
ing to improved outcomes.
Although it seems intuitive that implanting BiVAD early 
during initial surgery would improve outcomes in patients 
who are at risk for RVF, and thereby prevent end organ dys-
function and associated complications, supporting data 
are lacking. To the best of our knowledge, there have been 
only two studies showing outcome benefit for planed vs 
delayed RVAD implantation, while others showed either no 
benefit or mixed results (15,16,28,34). However, it is impor-
tant to note that these were all retrospective studies with 
smaller number of patients, and further research is neces-
sary to provide more accurate evidence. Clinical expertise 
and judgment will continue to guide decision making until 
more evidence becomes available.
PATHOPHYSiOLOgY AND PrOPOSeD MeCHANiSMS OF 
rigHT VeNTriCuLAr FAiLure
Factors determining right ventricular (RV) output and func-
tion include RV preload, afterload, and contractility. Chang-
es in physiology following LVAD affect all these RV output 
determinants and may lead to acute RV failure.
RV preload increases as a result of increased left ventricu-
lar (LV) output which might increase up to 100% following 
LVAD implantation (35). In addition, patients often receive 
substantial amount of fluids and blood products during 
perioperative period. This acute increase in preload leads 
to overstretching of cardiac myofibrils beyond the point 
of optimal contractility based on Frank Starling principle, 
and decreased RV stroke volume. Furthermore, increase in 
RV preload may lead to RV annular dilatation and tricuspid 
regurgitation adding to RV demand.
It is well known that the most common cause of RVF is LV 
failure (36). Left ventricular end diastolic pressure (LVEDP) 
is transmitted into increased pulmonary pressure leading 
to increased RV afterload and pulmonary hypertension 
(PHTN). LVAD implantation directly influences this mech-
anism, leading to decreases in RV afterload and in many 
cases resolution of PHTN (17,37,38). The time frame in 
which this occurs is variable. It is important to note that 
PHTN resolution is not universal, such as in cases of prima-
ry PHTN and PHTN related to pulmonary disease, as well 
as when pulmonary vasculature remodeling has already 
taken place.
Contractility of RV is influenced by LV function through 
the concept of ventricular interdependence. Effect of 
ventricular interdependence is most prominent in a 
setting of loading changes such as after LVAD im-
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plantation, and has an important role in pathophysiology 
of RV dysfunction following LVAD (39). It has been sug-
gested that substantial amount of RV systolic pressure 
and stroke volume results from LV contraction, and that 
interventricular septum plays the most important role 
(40). Structural organization and direction of myofibrils 
in the interventricular septum resembles more closely to 
the structure of left ventricular free wall where fibers are 
arranged in an oblique fashion as opposed to right ven-
tricle, where mostly transverse and longitudinal fiber ori-
entation is found. As septum contracts it contributes to 
contraction effort of RV free wall and also serves as its 
support structure. The dependence of RV output to inter-
ventricular septum and LV contractility has been proven 
in many animal models (41-43).
FACTOrS PreDiCTiNg rigHT VeNTriCuLAr FAiLure 
FOLLOWiNg LeFT VeNTriCuLAr DeViCe iMPLANTATiON
RVF complicating LVAD implantation is associated with 
worse postoperative mortality and morbidity includ-
ing worse end-organ function, longer hospital length of 
stay, and lower success of BTT therapy (10,11,15,27). Im-
portance of RVF and its predictors in a setting of LVAD 
implantation has been recognized early, as evidenced by 
abundant number of attempts to identify independent 
risk factors and develop RVF predictor scores. However, 
most of available literature are retrospective studies from 
single institutions that have similar limitations, including 
small sample size, lack of score validation, and for some 
earlier studies inclusion of patients receiving pulsatile 
LVADs only. Additional factors making evaluation and 
comparison of different predictor models and respective 
risk scores difficult is poor consistency in definition of RVF 
outcome, heterogeneity of variables considered in con-
struction of prediction models, and variability in inclusion 
of BTT and DT patients. Multivariate regression analysis 
was used to identify predictors in all studies except one, 
which employed a novel decision tree prediction model. 
Models also differ in determination of multivariate analy-
sis endpoint, with some focusing on RVF and others on 
mortality.
As already indicated, available prediction models differ 
with respect to inclusion of different types of LVADs. The 
next few sections provide a summary of most important 
pertinent studies in a chronological order, starting with 
those involving patients receiving pulsatile flow LVADs 
and moving toward combination cohorts and newer 
generation continuous LVADs cohorts only.
Destination therapy risk score (DTRS) was based on anal-
ysis of a cohort that included 222 patients receiving pul-
satile flow LVADs for DT (44). Variables of interest includ-
ed demographic characteristics, cardiac and noncardiac 
comorbidities, hemodynamic and laboratory parameters. 
Model was developed to predict 90-day in-hospital mor-
tality (N = 27%), rather than RV failure directly, and identi-
fied platelet count ≤148 × 103/mcgL, serum albumin ≤3.3 
g/dL, international normalization ratio (INR)>1.1, vasodila-
tor therapy at time of implantation, mean pulmonary ar-
tery pressure ≤25.3 mm Hg, aspartate aminotransferase 
>45 U/dL, hematocrit <34%, blood urea nitrogen >51 U/
dL, and lack of intravenous inotropic support as statistically 
significant predictors. A weighted risk score was assigned 
to each of the above nine variables to develop DTRS. Dis-
crimination C-statistic for DTRS was good (C-statistic value 
0.89; sensitivity, 82.6%; and specificity, 80.0% at P = 0.24). Pa-
tients were divided into 4 operative risk categories for 90-
day in-hospital mortality. The observed survival to hospital 
discharge in low-, medium-, high-, and very high-risk op-
erative candidates was 87.5%, 70.5%, 26%, and 13.7%, and 
1-year survival was 81.2%, 62.4%, 27.8%, and 10.7%, respec-
tively. Although this was one of the most commonly used 
scores clinically, its utility is questionable in today’s era of 
newer generation continuous flow LVADs predominance. 
A study evaluating DTRS for continuous LVADs found that 
the score was able to discriminate statistically significant 
differences in survival only for DT, and not BTT patients, but 
with poor discrimination in both groups (C-statistic 0.54 
and 0.58, for DT and BTT respectively) (45) ·
Another earlier model developed based on analysis of pul-
satile flow LVAD data from University of Pennsylvania (28) 
included 266 patients and looked at a total of 36 demo-
graphic, clinical, hemodynamic, and laboratory param-
eters. The endpoint was RVF, defined as a need for RVAD 
placement, and the incidence was 37%. In this series, mul-
tivariate analysis identified RV stroke work index ≤0.25 mm 
Hg × L/m2 (odds ratio [OR] 5.1), severe pre-operative RV 
dysfunction (OR 5.0), pre-operative creatinine ≥1.9 mg/
dL (OR 4.8), previous cardiac surgery (OR 4.5), and systol-
ic blood pressure ≤96 mm Hg (OR 2.9) as important pre-
dictors for RVF. Authors emphasized severe preoperative 
RV failure as likely the most significant factor determining 
which patients would require BiVAD, which was substanti-
ated by low RVSWI and severe echocardiographic RV dys-
function identified as two strongest predictors of need for 
biventricular support (28). However, this score, along with 
the following two (RVFRS and Drakos score) were evalu-
ated in a smaller European study, involving 59 LVAD im-
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plantations (33). Authors demonstrated failure to predict 
the need for RV support in their cohort with all three pro-
posed risk scores (33).
One of first RVF predictor models to include both pulsatile 
and continuous flow LVADs was RVFRS (22). It was gener-
ated based on analysis of 197 LVADs with RVF incidence 
of 35%, defined as a need for post-operative intravenous 
inotrope support for >14 days, inhaled nitric oxide for >48 
h, right-sided circulatory support, or hospital discharge on 
an inotrope. After analysis of commonly collected preop-
erative clinical, laboratory, hemodynamic, and echocardio-
graphic variables, the authors identified predictors for RVF 
following LVAD; need for vasopressor, AST>80 IU/L, biliru-
bin >2.0 mg/dL, and creatinine >2.3mg/dL and developed 
RVFRS as a sum of points awarded for presence of each of 
the 4 pre-operative variables (vasopressor requirement – 4 
points, AST>80 IU/L – 2 points, bilirubin >2.0 mg/dL – 2.5 
points and creatinine >2.3mg/dL – 3 points) (22). When ap-
plied to study sample, the score had 88% specificity, 35% 
sensitivity, 80% positive predictive value (PPV) and 80% 
negative predictive value (NPV). Compared to previously 
reported predictor models, this score had good C-statistic 
of 0.73 (95% confidence interval [CI] 0.65-0.81).
Another study including both pulsatile and continuous 
flow LVADs (27) provided multivariate analysis involving 
demographic, hemodynamic, laboratory, and echocardio-
graphic variables from 175 patients with endpoint of RVF 
with incidence of 44%, and RVF defined as a need for in-
haled nitric oxide for ≥48 hours or intravenous inotropes 
for >14 days and/or RVAD implantation. Score was devel-
oped as a sum of points assigned to each preoperative 
variable identified by multivariate model including preop-
erative need for intraaortic balloon pump (IABP), increased 
pulmonary vascular resistance ( PVR), inotrope dependen-
cy, obesity, DT, angiotensin-converting enzyme inhibitor/
aangiotensin receptor blocker (ACE/ARB) and beta-blocker 
(27). The risk score was broken into 4 categories, and the C-
statistic for the score was 0.743 ± 0.037. Authors also com-
pared this score to previously described RVFRS by applying 
that risk score’s point values to their study population and 
found the C-statistic for RVFRS of only 0.61 ± 0.04 (0.73 re-
ported in RVFRS study).
A study from University of Pittsburg (46) was the only one 
employing different methodology: a decision tree algo-
rithm instead of multivariate analysis to identify predic-
tors. It has been suggested that this prognostic tool might 
be superior to multivariate logistic regression with high 
classification accuracy and simple and intuitive represen-
tation of gathered data. This study involved 183 patients 
who received both pulsatile and continuous LVADs with 
endpoint of RVAD implantation as surrogate measure for 
RV failure occurring in 44% of patients. Final decision tree 
model comprised o8 preoperative variables; transpulmo-
nary gradient (TPG), age, right atrial pressure (RAP), INR, 
heart rate, white blood count (WBC), alanine aminotrans-
ferase (ALT), and number of inotropic agents (46). This 
type of analysis seems to be more easily interpreted and 
might be useful in determining synergistic, nonlinear in-
teractions among postoperative variables. It should be in-
vestigated and validated further, preferably including larg-
er patient population.
Given poor predictive value of DTRS in patients with con-
tinuous flow LVAD, a study involving 1122 patients from a 
large multicenter clinical trial data set receiving HeartMate 
II LVADs for both DT and BTT was performed and identified 
significant predictors of 90-day mortality including older 
age, lower albumin, higher INR, and center volume <15 
(47). As indicated, the study endpoint was defined as 90 
day mortality and the incidence was 13%. Patients were 
divided into derivation (DC) and validation (VC) cohort. A 
weighted HeartMate II risk score (HMRS) was developed 
and patients were stratified in low-, medium-, or high-risk 
groups. Reported mortality was significantly different in DC 
low, medium, and high HMRS groups (4%, 16%, and 29%, 
respectively). Corresponding mortality in VC was also sig-
nificantly different between groups (8%, 11%, and 25%, re-
spectively). Reported C-statistic was 0.71 (95% CI 0.66-0.75) 
and it was compared to end stage liver disease (MELD) 
score and DTRS for predicting 90-day mortality, with cor-
responding C-statistic 0.66 (95% CI 0.61-0.70) and 0.6 (95% 
CI 0.50-0.65), respectively.
Study from University of Pennsylvania involving 218 pa-
tients (48) receiving continuous flow LVADs found 5 pre-
operative predictors for RV failure: central venous pressure 
>15 mm Hg (OR 2.0, “C”), severe RV dysfunction (OR 3.7, “R”), 
preoperative intubation (OR 4.3, “I”), severe tricuspid regur-
gitation (OR 4.1, “T”), and heart rate >100 (OR 2.0, Tachycar-
dia - “T”). A quantitative preoperative risk score – CRITT was 
developed without weighing variables based on their re-
spective odds ratios by assigning score of 0 or 1 depending 
on presence or absence of respective variables (48). Based 
on the model, authors suggested an isolated LVAD for a 
score of 0 or 1 and BIVAD for scores of 4 or 5. Those with 
scores 2 and 3 represent patients who might tolerate 
isolated LVAD with likely need for temporary medi-
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cal or RVAD support as clinically indicated. Authors report-
ed C-statistic of 0.80 ± 0.04, sensitivity of 87%, specificity of 
75%, and NPV of 93% (48).
With improvements in ultrasound technology, there have 
been attempts to include echocardiographic variables in 
predictor models. It has been suggested that increased 
right to left ventricle diameter ratio is a strong predictor 
of RVF after LVAD, based on prospective TEE preoperative 
measurements (17). This finding was confirmed in another 
study based on analysis of patients implanted with contin-
uous flow LVADs that included 26 TTE parameters and also 
adjusted for previously identified clinical predictors (49).
Other echocardiographic variables that have been iden-
tified as significant predictors of survival or RVF following 
LVAD include tricuspid dilatation, tricuspid incompetence, 
small left ventricular end diastolic diameter (LVEDD<63 
mm), and early systolic equalization of RV and right atri-
al pressure demonstrated as decreased time interval be-
tween onset and cessation of tricuspid regurgitation flow 
corrected for heart rate (TRDc) (17,24,30).
In summary, there has been a lot of effort to identify risk 
factors for RVF following LVAD and develop clinically use-
ful predictor scores to help improve overall survival. How-
ever, most models and respective scores faced limitations 
making their implementation and clinical usefulness ques-
tionable. Regardless, value of these studies lies in providing 
information on potential key predictors for RVF that can 
be taken into account in clinical decision making. Further 
investigation of current predictors and existing scores, as 
well as new studies involving larger patient populations 
and more sophisticated statistical prediction models, are 
necessary.
Our iNSTiTuTiONAL APPrOACH FOr MiNiMiZiNg riSK 
FOr rigHT VeNTriCuLAr FAiLure AFTer LVAD
It has been suggested that central venous pressure (CVP) 
is not a reliable surrogate of intravascular volume status. 
Nonetheless, elevated CVP has been identified as one of 
the significant predictors of RVF after LVAD, and it is still 
used in clinical decision making. Empirical value that we 
use as a target in our practice with LVAD patients is CVP<15 
mm Hg. Aggressive intravenous fluid administration in a 
setting of already distended RV with decreased contractile 
capability will not increase RV output. On the contrary, it 
will lead to further increase in CVP, hepatic and systemic 
congestion, and reduced transmyocardial perfusion 
pressure gradient. Therefore, our approach is to be judi-
cious with intravenous (IV) fluid administration, and rely on 
increasing inotropic support (milrinone, dobutamine) to 
help RV contractility. Also, decrease in pulmonary afterload 
is achieved with adequate ventilation (to avoid hypoxic 
pulmonary vasoconstriction) and/or use of inhaled Flolan 
(epoprostenol sodium) and/or NO (nitric oxide). Maintain-
ing continuous perfusion pressure >70 mm Hg to preserve 
RV function and transmyocardial gradient is imperative, 
and often requires use of one or more vasopressors (nor-
epinephrine, vasopressin). IABP is sometimes required to 
optimize RV function in coronary artery disease patients by 
increasing perfusion of coronary arteries.
Importance of interdisciplinary approach and excellent 
communication between all team members involved in 
perioperative management (surgeon, anesthesiologist, 
critical care and nursing staff ) cannot be overemphasized. 
Transesophageal echocardiogram (TEE) surveillance for ad-
equate ventricular filling and optimal midline septal posi-
tion is important to anticipate, treat and prevent a suction 
event. In case of the suction event, commonly employed 
interventions include maintaining perfusion pressure >70 
mm Hg, and careful challenging with iv fluids and tempo-
rarily allowed increase in CVP>15 mm Hg. In the event of 
persistently inadequate LVAD filling despite higher CVP 
(15-20 mm Hg), maximal inotropic and vasopressor sup-
port, and adequate respiratory function (absence of aci-
dosis, Pao2>110, Paco2<40), RV mechanical support is com-
monly the next step in patient management.
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